BioInformant

Your Global Leader in Stem Cell Market Research

You are here: Home / Archives for Cell Therapy / CAR-T

T Cells For Immune Defense

By

Can T cells be an effective approach to cancer treatment? CAR T-cell therapy, as this cutting-edge treatment is called, uses a patient’s own immune system to help fight cancers in the body. The result is a natural treatment that proves effective against a variety of blood cancers and may have hope for other cancers in the future as well.

T-cells are the workhorses of our immune system and they play a key role in directing the immune response and killing cells infected by pathogens.

Using T Cells For Cancer Treatment

In this article:

  1. CAR-T Cell Therapy Treatments for Treatment of Cancer
  2. What Causes Cancer?
  3. How Does the Immune System Work – and What Are Its Limits?
  4. What Is Immunotherapy?
  5. Are There Different Types of Immunotherapy?
  6. What Are T Cells?
  7. What Is CAR-T Cell Therapy?
  8. How Does CAR-T Cell Therapy Work?
  9. Who Is CAR-T Cell Therapy Right For?
  10. Why Doesn’t CAR-T Cell Therapy Work for Solid Tumors?
  11. Are There Any Risks?
  12. What Are the Benefits of CAR-T?
  13. How Effective Is CAR-T Treatment?
  14. Progress in CAR-T Cell Therapy Development

[Read more…]

Allogene Therapeutics Raises Another $120M as CAR-T Funding Frenzy Continues

By

Allogene Therapeutics, a clinical-stage biotechnology company pioneering the development of allogeneic CAR T therapies for cancer, announced that it completed a $120 million private financing of Convertible Notes.

According to the company, “Allogene is advancing its allogeneic CAR T cell portfolio, which includes rights to 16 preclinical CAR T cell therapy targets and U.S. rights to UCART19, an allogeneic CAR T cell therapy candidate that is being developed for the treatment of CD19-expressing hematological malignancies. In partnership with Servier, UCART19 is in Phase 1 development for the treatment of relapsed/refractory acute lymphoblastic leukemia (ALL).” [Read more…]

Novartis Receives Health Canada Approval of its CAR-T cell therapy, Kymriah™

By

  • Kymriah, the first chimeric antigen receptor T cell (CAR-T) therapy approved in Canada, is manufactured individually for each patient
  • Novartis is working with qualified treatment centres to prepare for the delivery of this treatment for relapsed/refractory (r/r) pediatric and young adult B-cell ALL and adult r/r DLBCL indications

DORVAL, QC, Sept. 6, 2018 – Novartis is pleased to announce that following a Priority Review, Health Canada has approved Kymriah™ (tisagenlecleucel/ CTL019) the first chimeric antigen receptor T cell (CAR-T) therapy to receive regulatory approval in Canada.

Kymriah, a CD19-directed genetically modified autologous T-cell immunocellular therapy, is approved to treat two life-threatening cancers that have limited treatment options and historically poor outcomes, demonstrating the critical need for new therapies for these patients. [Read more…]

CAR-T Manufacturing | Novartis Selects French CDMO CELLforCURE

By

CELLforCURE is a French pharmaceutical group that is authorized to do CAR-T manufacturing at its bioproduction site in Les Ulis (Essonne). CELLforCURE holds two Good Manufacturing Practice (GMP) certificates that allows it to manufacture experimental and commercial cell and gene therapies.

On July 10, 2018, CELLforCURE signed an agreement to manufacture CAR-T products for Novartis. Under the terms of the agreement, CELLforCURE will produce cancer CAR-T therapies (“chimeric antigen receptor T-cells”).

Production is scheduled to begin in 2019 following transfer of Novartis’ CAR-T manufacturing technology to CELLforCURE. [Read more…]

What is CAR-T Cell Therapy? | CAR-T Definition

By

CAR-T cell therapy is as a type of immunotherapy that teaches T cells to recognize and destroy cancer. CAR-T cell therapy has demonstrated promising results in a range of patients from young and old. In some patients, this can lead to the total elimination of the cancer. In others, there is a significant improvement of the disease.

For those who are facing cancer, it is important to answer the question “What is CAR-T?” This guide will answer the most common questions about CAR-T cell therapy for readers who want to understand this novel technology platform for treating cancer.  [Read more…]

BioInformant's World-Class Clients